$MNKD News

MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload - Slideshow

MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF - Slideshow

MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript

Wells Fargo Maintains Overweight on MannKind, Raises Price Target to $14

MannKind Reports Topline Results From INFLO-1, Phase 1b Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Dry Powder Inhalation In Patients With Idiopathic Pulmonary Fibrosis

FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease

MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload Transcript

MannKind Announces $50M Private Placement Financing, Closing Expected On Or About July 24

MannKind Receives FDA Approval Of Its Furoscix ReadyFlow For Treatment Of Edema In Adults With Heart Failure Or Chronic Kidney Disease

MannKind Awarded Grant From Breakthrough T1D To Support Ongoing INHALE-1ST Clinical Study Evaluating Initiation Of Afrezza Inhalation Powder Shortly After Type 1 Diabetes Diagnosis In Pediatric Patients

Reported Friday, MannKind's Afrezza Data At ADA Highlight Pediatric Safety, Gestational Diabetes Efficacy And AID System Compatibility Following May 2026 FDA Pediatric Approval

MannKind Announces Key Clinical Execution Milestones In The Development Of Nintedanib DPI For Idiopathic Pulmonary Fibrosis

MannKind At An Inflection Point: Pediatric Expansion Drives The Story

MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript

MannKind To Host Conference Call At 4:30 p.m. ET On May 29 To Discuss FDA Approval Of Pediatric Use Of Afrezza

MannKind Wins FDA Approval For Pediatric Use Of Inhaled Insulin Afrezza In Children Ages 6 And Older With Diabetes

MannKind To Present New Clinical And Real‑World Data On Afrezza Inhalation Powder And Analyses Of Furoscix In Patients With Co-Morbidities At The American Diabetes Association's 2026 Scientific Sessions, June 5-8

RBC Capital Maintains Sector Perform on MannKind, Raises Price Target to $4.75

MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript

Wells Fargo Maintains Overweight on MannKind, Raises Price Target to $10